EUVIMEDDescoperă EUVIMED
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials

Stephen D Silberstein, Hans-Christoph Diener, David W Dodick iD, Katherine Sommer, Richard B Lipton iD

Headache: The Journal of Head and Face Pain · 2024

DOI: 10.1111/head.14743 ↗

At a glance

Klinische Studie (Phase III) in Headache: The Journal of Head and Face Pain, 2024. Written by Stephen D Silberstein and 4 co-authors. Institution: Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Botulinum Toxins, Type A, Migraine Disorders. Cited 9 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: AbbVie.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Objective To characterize the long‐term (56‐week) benefits of continuous onabotulinumtoxinA treatment response in individuals with chronic migraine (CM) who achieved reduction to

Subjects

MeSH terms (MEDLINE)

Botulinum Toxins, Type AMigraine DisordersHumansAdultMaleFemaleDouble-Blind MethodMiddle AgedChronic DiseaseNeuromuscular AgentsQuality of LifeOutcome Assessment, Health Care

Author keywords

botulinum toxin type Aheadachepatient‐reported outcome measuresquality of life

Substances

Botulinum Toxins, Type Aonabotulinum toxin ANeuromuscular Agents

Authors and institutions

  • Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.
  • Department of Neurology, Mayo Clinic, Phoenix, Arizona, USA.
  • Atria Academy of Science and Medicine, New York, New York, USA.
  • Allergan, an AbbVie Company, Irvine, California, USA.
  • Department of Neurology, Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York, USA.

ORCID profiles: David W Dodick, Richard B Lipton

Funding

  • AbbVie

Cite

APA

Silberstein, S. D., Diener, H. C., Dodick, D. W., Sommer, K., & Lipton, R. B. (2024). Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14743

Vancouver

Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14743

BibTeX
@article{Silberstein2024,
  author = {Silberstein, Stephen D and Diener, Hans-Christoph and Dodick, David W and Sommer, Katherine and Lipton, Richard B},
  title = {Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2024},
  doi = {10.1111/head.14743}
}
Start for free →